What one share of Sagimet Biosciences holds
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.
Sagimet Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.25 |
|---|---|
| Cash and investments | $4.85 |
| Book value | $4.82 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$165.20 | — | — | — | −$1,010 |
| 2023 | $0.19 | −$2.66 | — | — | — | $8.71 |
| 2024 | — | −$1.45 | — | — | — | $4.97 |
| 2025 | — | −$1.58 | — | — | — | $3.44 |
Common questions about Sagimet Biosciences
How much does one share of Sagimet Biosciences earn?
Over the last 12 months, Sagimet Biosciences lost $1.25 for each share.
Does Sagimet Biosciences pay a dividend?
Sagimet Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Sagimet Biosciences’s book value per share?
Sagimet Biosciences’s book value is $4.82 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Sagimet Biosciences have?
Each share of Sagimet Biosciences has $4.85 of cash and investments, as of June 30, 2026.
Has Sagimet Biosciences bought back shares?
Sagimet Biosciences’s share count rose about 17420% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.